Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial

Further Publications Dermatology

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study

Lancet

Kavanagh D, Bomback AS, Vivarelli M, Nester CM, Remuzzi G, Zhao MH, Wong EKS, Wang Y, Krishnan I, Schuhmann I, Trapani AJ, Webb NJA, Meier M, Israni RK, Smith RJH, APPEAR-C3G investigators

doi: 10.1016/S0140-6736(25)01148-1

Further Publications Dermatology

Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial

Lancet

Taher AT, Al-Samkari H, Aydinok Y, Besser M, Boscoe AN, Dahlin JL, De Luna G, Estepp JH, Gheuens S, Gilroy KS, Glenthøj A, Sim Goh A, Iyer V, Kattamis A, Loggetto SR, Morris S, Musallam KM, Osman K, Ricchi P, Salido-Fiérrez E, Sheth S, Tai F, Tevich H, Uhlig K, Urbstonaitis R, Viprakasit V, Cappellini MD, Kuo KHM, ENERGIZE investigators

doi: 10.1016/S0140-6736(25)00635-X

Immune Response

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Lancet

Tindale LC, Richardson JS, Anderson DM, Mendy J, Muhammad S, Loreth T, Tredo SR, Ramanathan R, Jenkins VA, Bedell L, Ajiboye P, EBSI-CV-317-005 Study Group

doi: 10.1016/S0140-6736(25)00372-1

Fibromyalgia

Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial

Ann Rheum Dis

Rasmussen MU, Christensen R, Wæhrens EE, Henriksen M, Duhn PH, Bliddal H, Amris K

doi: 10.1016/j.ard.2025.07.008

Alopecia Areata

Efficacy and safety of Cinainu in pediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase 2/3 trial

Br J Dermatol

Blume-Peytavi U, Piraccini BM, Reygagne P, Guiraud J, Mukherjee B, Guichard A, Liu J, Pralong W, Harti S

doi: 10.1093/bjd/ljaf279

Rheumatoid Arthritis

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Ann Rheum Dis

Taylor PC, Mease PJ, de Vlam K, Mpofu S, Wetzel D, Stevens AM, Wiens B, Koskinen LO, Ohlman S, Feldwisch J, Frejd FY, Brun NC, Brandt-Juergens J, Drescher E, Dokoupilova E, Rowińska-Osuch A, Abdel-Kader Martin N, Behrens F

doi: 10.1016/j.ard.2025.02.019

Immunodeficiency

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

Lancet

Colson AE, Mills AM, Ramgopal MN, Bettacchi C, Osiyemi OO, Hinestrosa F, Crofoot G, Katner HP, Gatanaga H, Johnson M, Diamond TL, Barninger E, Eves K, Su FH, Xu Y, Klopfer SO, Stamm LM, Fox MC, Lahoulou R

doi: 10.1016/S0140-6736(25)01948-8

Rheumatoid Arthritis

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Lancet Rheumatol

Cope AP, Jasenecova M, Vasconcelos JC, Qureshi S, van Schie KA, Filer A, Raza K, D'Agostino MA, McInnes IB, Siebert S, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Mankia K, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga TWJ, Toes REM, Georgiou E, Kelly J, Murphy C, Prevost AT, ALTO Study Investigators

doi: 10.1016/S2665-9913(25)00371-6

Melanoma and Skin Cancer

O04 Mission EB -mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: a randomised, double-blinded, placebo controlled, crossover trial

Br J Dermatol

Bageta ML, López Balboa P, Bursnall M, Wilson I, Biggs K, Glover R, Hutchence K, Ditta S, Julious S, Poudel P, Nadeem M, Papaioannou D, Ogboli M, Lovgren ML, McGrath J, Cooper C, Petrof G, Martinez AE

doi: 10.1093/bjd/ljaf465.004

Related content

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study

Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial

Efficacy and safety of Cinainu in pediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase 2/3 trial

Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

O04 Mission EB -mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: a randomised, double-blinded, placebo controlled, crossover trial